BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 38632167)

  • 1. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress.
    Liu Y; Li C; Liu H; Tan S
    Arch Pharm Res; 2024 Apr; ():. PubMed ID: 38632167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review).
    Li ZN; Luo Y
    Oncol Rep; 2023 Jan; 49(1):. PubMed ID: 36367182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy.
    Xie X; Zhang N; Li X; Huang H; Peng C; Huang W; Foster LJ; He G; Han B
    Bioorg Chem; 2023 Oct; 139():106721. PubMed ID: 37467620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.
    Ren X; Li T; Zhang W; Yang X
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitors as promising agents for radiotherapy.
    Kabakov AE; Kudryavtsev VA; Gabai VL
    J Mol Med (Berl); 2010 Mar; 88(3):241-7. PubMed ID: 19946660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganetespib: research and clinical development.
    Jhaveri K; Modi S
    Onco Targets Ther; 2015; 8():1849-58. PubMed ID: 26244021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: targeting hsp90--who benefits and who does not.
    Scaltriti M; Dawood S; Cortes J
    Clin Cancer Res; 2012 Sep; 18(17):4508-13. PubMed ID: 22718860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
    Neckers L; Neckers K
    Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated patent review of anticancer Hsp90 inhibitors (2013-present).
    Li L; Chen NN; You QD; Xu XL
    Expert Opin Ther Pat; 2021 Jan; 31(1):67-80. PubMed ID: 32990109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapies with HSP90 inhibitors against colorectal cancer.
    Kryeziu K; Bruun J; Guren TK; Sveen A; Lothe RA
    Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):240-247. PubMed ID: 30708039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.